“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
How do today’s CEOs and founders find the balance between planning and entrepreneurship? Check out the latest episode of the Biorasi Few & Far...
Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...